| abstract |
The present specification relates to a T cell receptor (TCR) for binding to a cancer cell in combination with a tumor associated antigen (TIA), a T cell expressing the receptor, a method for producing the receptor, and a method for treating cancer using the receptor. In particular, the present specification relates to TCRs and variants thereof that bind to HLA class I or class II molecules containing a peptide (e.g., IGF2BP3-001) having the amino acid sequence of KIQEILTQV (SEQ ID NO: 1). The present specification further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present specification relates to immunotherapy for cancer. The present specification also relates to tumor-associated T cell (CTL) peptide epitopes used alone or in combination with other tumor-associated peptides (stimulating anti-tumor immune responses or in vitro stimulating T cells and active pharmaceutical ingredients of vaccine complexes transferred to patients). Peptides that bind to major histocompatibility complex (MHC) molecules or peptides of this type may also be targets for antibodies, soluble T cell receptors, and other binding molecules. |